Table 5.
Immune responses as poliovirus type-2 neutralising antibody titres in the total study population
| Candidate 1 (n=15) | Candidate 2 (n=15) | |
|---|---|---|
| Geometric mean titre (95% CI) | ||
| Day 0 | 93·3 (55·3–170·0) | 52·8 (25·2–123·1) |
| Day 28 | 680·9 (367·8–1098) | 575·0 (330·1–871·9) |
| Geometric mean fold change in titre (95% CI) | ||
| Day 28 | 7·3 (3·8–13·5) | 10·9 (4·5–24·6) |
| Median titre (IQR; Q1–Q3), (95% CI) | ||
| Day 0 | 56·9 (40·6–147·4; 106·7), (36·0–181·0) | 36·0 (22·6–81·3; 58·6), (22·6–90·5) |
| Day 28 | 1152 (650–1448; 798), (576·0–1448) | 724·1 (408·6–1152·1; 743·5), (362·0–1152) |
| Median fold change in titre (IQR; Q1–Q3), (95% CI) | ||
| Day 28 | 8·00 (2·6–22·8; 20·2), (2·00–20·1) | 12·73 (4·1–38·2; 34·1), (3·18–25·5) |
| Seroprotection, n (%), 95% CI | ||
| Day 0 | 15 (100%), 78·2–100 | 14 (93%), 68·1–99·8 |
| Day 28 | 15 (100%), 78·2–100 | 15 (100%), 78·2–100 |
| Seroconversion, n (%), 95% CI | ||
| Day 28* | 10 (83%), 51·6–97·9 | 11 (85%), 54·6–98·1 |
95% CIs were calculated with the Clopper-Pearson method.
*
Three participants given candidate 1 and two participants given candidate 2 had baseline titres close to the upper limit of quantitation so it was not possible to measure a 4-fold increase.